INCY Fail-to-Deliver

Incyte Corporation (INCY) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $19.74B, listed on NASDAQ, employing roughly 2,617 people, carrying a beta of 0.80 to the broader market. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. Led by William J. Meury, public since 1993-11-04.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-04-29
Latest FTD Quantity
189
Latest Price
$97.74
30-Day Avg FTD
7.9K
30-Day Total FTD
237.9K

Showing 30 days of SEC fail-to-deliver data for Incyte Corporation.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked INCY fail to deliver questions

What is the latest INCY fail-to-deliver count?
As of Apr 29, 2026, Incyte Corporation (INCY) fail-to-deliver quantity is 189 shares, with a 30-day average of 7.9K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do INCY FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.